Assessing the Clinical Utility of Measuring Insulin-like Growth Factor Binding Proteins in Tissues and Sera of Melanoma Patients

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2008 Nov 26

PMID 19025658

Citations 8

Authors

Jessie Z Yu

Melanie A Warycha

Paul J Christos

Farbod Darvishian

Herman Yee

Hideko Kaminio

Russell S Berman

Richard L Shapiro

Michael T Buckley

Leonard F Liebes

Anna C Pavlick

David Polsky

Peter C Brooks

Iman Osman

Affiliations

Soon will be listed here.

Abstract

Background: Different Insulin-like Growth Factor Binding Proteins (IGFBPs) have been investigated as potential biomarkers in several types of tumors. In this study, we examined both IGFBP-3 and -4 levels in tissues and sera of melanoma patients representing different stages of melanoma progression.

Methods: The study cohort consisted of 132 melanoma patients (primary, n = 72; metastatic, n = 60; 64 Male, 68 Female; Median Age = 56) prospectively enrolled in the New York University School of Medicine Interdisciplinary Melanoma Cooperative Group (NYU IMCG) between August 2002 and December 2006. We assessed tumor-expression and circulating sera levels of IGFBP-3 and -4 using immunohistochemistry and ELISA assays. Correlations with clinicopathologic parameters were examined using Wilcoxon rank-sum tests and Spearman-rank correlation coefficients.

Results: Median IGFBP-4 tumor expression was significantly greater in primary versus metastatic patients (70% versus 10%, p = 0.01) A trend for greater median IGFBP-3 sera concentration was observed in metastatic versus primary patients (4.9 microg/ml vs. 3.4 microg/ml, respectively, p = 0.09). However, sera levels fell within a normal range for IGFBP-3. Neither IGFBP-3 nor -4 correlated with survival in this subset of patients.

Conclusion: Decreased IGFBP-4 tumor expression might be a step in the progression from primary to metastatic melanoma. Our data lend support to a recently-described novel tumor suppressor role of secreting IGFBPs in melanoma. However, data do not support the clinical utility of measuring levels of IGFBP-3 and -4 in sera of melanoma patients.

Citing Articles

Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival.

Rius F, Papaiz D, Azevedo H, Ayub A, Pessoa D, Oliveira T Clin Epigenetics. 2022; 14(1):68.

PMID: 35606887 PMC: 9128240. DOI: 10.1186/s13148-022-01291-x.

Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma.

Borden E, Adams A, Buetow K, Wilson M, Bauman J, Curiel-Lewandrowski C Cancers (Basel). 2022; 14(1).

PMID: 35008167 PMC: 8749980. DOI: 10.3390/cancers14010003.

Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo.

Contois L, Akalu A, Caron J, Tweedie E, Cretu A, Henderson T Angiogenesis. 2014; 18(1):31-46.

PMID: 25249331 PMC: 4281512. DOI: 10.1007/s10456-014-9445-2.

IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.

Mosig R, Lobl M, Senturk E, Shah H, Cohen S, Chudin E J Ovarian Res. 2012; 5(1):3.

PMID: 22264331 PMC: 3271973. DOI: 10.1186/1757-2215-5-3.

Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis.

Contois L, Nugent D, Caron J, Cretu A, Tweedie E, Akalu A J Biol Chem. 2011; 287(3):1779-89.

PMID: 22134921 PMC: 3265860. DOI: 10.1074/jbc.M111.267732.

References

Rowinsky E, Youssoufian H, Tonra J, Solomon P, Burtrum D, Ludwig D . IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007; 13(18 Pt 2):5549s-5555s. DOI: 10.1158/1078-0432.CCR-07-1109. View

Tao Y, Pinzi V, Bourhis J, Deutsch E . Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007; 4(10):591-602. DOI: 10.1038/ncponc0934. View

Collett-Solberg P, Cohen P . The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am. 1996; 25(3):591-614. DOI: 10.1016/s0889-8529(05)70342-x. View

Girnita L, Shenoy S, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A . Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem. 2007; 282(15):11329-38. DOI: 10.1074/jbc.M611526200. View

Liu B, Lee K, Anzo M, Zhang B, Zi X, Tao Y . Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene. 2006; 26(12):1811-9. DOI: 10.1038/sj.onc.1209977. View

Garcia-Echeverria C, Pearson M, Marti A, Meyer T, Mestan J, Zimmermann J . In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004; 5(3):231-9. DOI: 10.1016/s1535-6108(04)00051-0. View

Ikonen M, Liu B, Hashimoto Y, Ma L, Lee K, Niikura T . Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci U S A. 2003; 100(22):13042-7. PMC: 240741. DOI: 10.1073/pnas.2135111100. View

Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M . IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature. 2008; 454(7202):345-9. DOI: 10.1038/nature07027. View

Gable K, Maddux B, Penaranda C, Zavodovskaya M, Campbell M, Lobo M . Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006; 5(4):1079-86. DOI: 10.1158/1535-7163.MCT-05-0397. View

10.

Ouban A, Muraca P, Yeatman T, Coppola D . Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003; 34(8):803-8. DOI: 10.1016/s0046-8177(03)00291-0. View

11.

Samani A, Brodt P . The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am. 2001; 10(2):289-312, viii. View

12.

Wajapeyee N, Serra R, Zhu X, Mahalingam M, Green M . Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008; 132(3):363-74. PMC: 2266096. DOI: 10.1016/j.cell.2007.12.032. View

13.

Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J . Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther. 2006; 5(12):3078-84. DOI: 10.1158/1535-7163.MCT-06-0424. View

14.

Debacq-Chainiaux F, Pascal T, Boilan E, Bastin C, Bauwens E, Toussaint O . Screening of senescence-associated genes with specific DNA array reveals the role of IGFBP-3 in premature senescence of human diploid fibroblasts. Free Radic Biol Med. 2008; 44(10):1817-32. DOI: 10.1016/j.freeradbiomed.2008.02.001. View

15.

Huang S, Ling T, Tseng W, Huang Y, Tang F, Leal S . Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. FASEB J. 2003; 17(14):2068-81. DOI: 10.1096/fj.03-0256com. View

16.

Damon S, Maddison L, Ware J, Plymate S . Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology. 1998; 139(8):3456-64. DOI: 10.1210/endo.139.8.6150. View

17.

Rajaram S, Baylink D, Mohan S . Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997; 18(6):801-31. DOI: 10.1210/edrv.18.6.0321. View

18.

Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K . High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 2006; 97(11):1182-90. PMC: 11158442. DOI: 10.1111/j.1349-7006.2006.00322.x. View

19.

Kucuk O, Sarkar F, Sakr W, Djuric Z, Pollak M, Khachik F . Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001; 10(8):861-8. View

20.

Durai R, Davies M, Yang W, Yang S, Seifalian A, Goldspink G . Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol. 2006; 28(6):1317-25. View